Medtronic SynchroMed II, Model 8637, (The SynchroMed II Pump is supplied in 20 ml or 40 ml reservoir size.) Sterilized using ethylene oxide. Product Usage: The pump is part of an infusion system that stores and delivers a prescribed drug to a specific site. The implantable components of the SynchroMed II infusion system include the pump, catheter, and catheter accessories. The SynchroMed II Programmable Pump is indicated when patient therapy requires the chronic infusion of the following drugs or fluids: Chronic intraspinal (epidural and intrathecal) infusion of preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, Chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, Chronic intrathecal infusion of Lioresal Intrathecal (baclofen Injection ) in the management of serve spasticity, Chronic Intravascular Infusion of Floxuridine (FUDR) or methotrexate for the treatment of primary or metastatic cancer.
Publicado el 3 de julio de 2013 · Inicio del retiro: 3 de junio de 2013
Resumen
FDA registra el retiro Z-1570-2013 de dispositivos médicos de Clase I, publicado el 3 de julio de 2013 e iniciado el 3 de junio de 2013. Empresa responsable: Medtronic Neuromodulation; Estado: Finalizado; Cantidad reportada: 261,109 total devices estimated implanted Worldwide; Lote: all SynchroMed II pumps. La Clase I indica una probabilidad razonable de consecuencias graves para la salud o muerte.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Medtronic is providing Healthcare Professionals with important safety information and patient management recommendations regarding the unintended delivery of drug during the priming bolus function for the SynchroMed implantable infusion pump. The unintended delivery of drug can contribute to patient overdose or underdose symptoms which may be clinically relevant.
Qué hacer
Voluntary: Firm initiated · Visit
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Medtronic Neuromodulation
- Distribuidor
- Worldwide Distribution - USA Nationwide
- Lote
- all SynchroMed II pumps
- Clasificación de riesgo
- Class I
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAInterStim SureScan MRI Leads 978A1 & 978B1: LEAD 978A128 ISTM MICRO 28CM SSMRI TINED 978A128 LEAD 978A133 ISTM28 de octubre de 2026
- FDAInterStim Percutaneous Extensions EXT 3560022 ISTM II PERC 3560022 EXT 3560030 ISTM MICRO PERC 356003028 de octubre de 2026
- FDAMedtronic 2x4 Pocket Adaptor Kit for Deep Brain Stimulation, Model 64002; Stimulator, electrical, implanted,3 de junio de 2026
- FDAMedtronic 1x4 Pocket Adaptor Kit for Deep Brain Stimulation, Model 64001; Stimulator, electrical, implanted,3 de junio de 2026
- FDASarns " TCM II Temperature Control Module The Sarns" TCM II Temperature Control Module is a source of3 de julio de 2013
- FDAMedtronic SynchroMed EL Programmable pumps, Models 8626, 8626L, 8627, 8627L, (The SynchroMed EL Pumps are3 de julio de 2013
Preguntas sobre este retiro
¿Medtronic SynchroMed II, Model 8637, (The SynchroMed II Pump is supplied in 20 ml or 40 ml reservoir size.) Sterilized using ethylene oxide. Product Usage: The pump is part of an infusion system that stores and delivers a prescribed drug to a specific site. The implantable components of the SynchroMed II infusion system include the pump, catheter, and catheter accessories. The SynchroMed II Programmable Pump is indicated when patient therapy requires the chronic infusion of the following drugs or fluids: Chronic intraspinal (epidural and intrathecal) infusion of preservative-free morphine sulfate sterile solution in the treatment of chronic intractable pain, Chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe chronic pain, Chronic intrathecal infusion of Lioresal Intrathecal (baclofen Injection ) in the management of serve spasticity, Chronic Intravascular Infusion of Floxuridine (FUDR) or methotrexate for the treatment of primary or metastatic cancer. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1570-2013 el 3 de julio de 2013. Peligro reportado: Medtronic is providing Healthcare Professionals with important safety information and patient management recommendations regarding the unintended delivery of drug during the priming bolus function for the SynchroMed implantable infusion pump. The unintended delivery of drug can contribute to patient overdose or underdose symptoms which may be clinically relevant.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Visit